HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation of the PercuSurge Guardwire Plus Temporary Occlusion and Aspiration System during primary angioplasty in acute myocardial infarction.

Abstract
Thirty patients with acute myocardial infarction (AMI) underwent primary angioplasty under distal protection of PercuSurge GuardWire Plus Temporary Occlusion and Aspiration System. Before angioplasty, protection of the distal circulation was achieved with the system, followed by balloon angioplasty and/or stenting and debris aspiration. Technical device success was 100%. Distal occlusion was well tolerated in all patients. Mean total distal occlusion time was 7.3 +/- 5.4 min. Macroscopically visible debris was aspirated from 29 cases (96.7%). Postprocedural Thrombolysis in Myocardial Infarction flow grade 3 was achieved in all cases (100%, vs. 16.7% at baseline). Myocardial blush flow grade 3 was achieved in 26 cases (86.7%). Regression of ST segment elevation >/= 50% was shown in 23 cases (76.7%). No patient developed angiographic evidence of no-reflow or distal embolization. Both angiographic and procedural success were 100%. The system is feasible, safe, and effective for distal protection against embolism during primary angioplasty in AMI.
AuthorsZheng Huang, Osamu Katoh, Shigeru Nakamura, Shinji Negoro, Tomoko Kobayashi, Jun Tanigawa
JournalCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (Catheter Cardiovasc Interv) Vol. 60 Issue 4 Pg. 443-51 (Dec 2003) ISSN: 1522-1946 [Print] United States
PMID14624419 (Publication Type: Evaluation Study, Journal Article)
CopyrightCopyright 2003 Wiley-Liss, Inc.
Topics
  • Aged
  • Aged, 80 and over
  • Angioplasty, Balloon
  • Balloon Occlusion (instrumentation)
  • Blood Flow Velocity
  • Embolism (prevention & control)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction (complications, therapy)
  • Prospective Studies
  • Stents
  • Suction (instrumentation)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: